<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664274</url>
  </required_header>
  <id_info>
    <org_study_id>061/C39-0</org_study_id>
    <secondary_id>1R03MH078098-01</secondary_id>
    <secondary_id>MRPC 2917</secondary_id>
    <nct_id>NCT00664274</nct_id>
  </id_info>
  <brief_title>Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia</brief_title>
  <acronym>COMT</acronym>
  <official_title>COMT Genotype and Response to Cognitive Remediation in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manhattan Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Manhattan Psychiatric Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will explore the relationship between catechol-O-methyltransferase (COMT)
      Val158/108Met genotype and response to a 12-week computerized neurocognitive rehabilitation
      (CRT) given to chronic schizophrenic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive deficits play a crucial role in both the pathogenesis and prognosis of
      schizophrenia. The COMT gene is functionally expressed in neural systems considered important
      in a range of healthy brain functions and brain disorders, including schizophrenia. The COMT
      Met allele has been shown to be associated with a lower activity form of COMT, and with
      better performance on neurocognitive tests, while the COMT Val allele is associated with
      poorer executive cognition. This study will investigate the relationship of COMT polymorphism
      in patients with chronic schizophrenia with the response to CRT targeting visuospatial
      processing, attention, and cognitive flexibility using MATRICS Consensus Cognitive Battery
      (MCCB) developed by the NIH-MATRICS initiative.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of the association of COMT Val108/158 Met genotype with the response to a computerized neurocognitive rehabilitation treatment in patients with chronic schizophrenia.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To expand the response to a computerized neurocognitive rehabilitation treatment in patients with chronic schizophrenia to other haplotypes or identified genes.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the differences in demographic variables (e.g. ethnicity, intellectual functioning as measured by WRAT III Reading test, and age) with response to computerized neurocognitive rehabilitation treatment in patients with chronic schizophrenia.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the differences between antipsychotic treatment and response to computerized neurocognitive rehabilitation treatment in patients with chronic schizophrenia.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Chronic Schizophrenia</condition>
  <arm_group>
    <arm_group_label>CRT Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive remediation therapy</intervention_name>
    <description>36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.</description>
    <arm_group_label>CRT Group</arm_group_label>
    <other_name>educational and behavioral training techniques</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>COMT Genotyping</intervention_name>
    <description>One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.</description>
    <arm_group_label>CRT Group</arm_group_label>
    <other_name>COMT polymorphism</other_name>
    <other_name>22q11.21-q11.23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participation in the active arm of the neurocognitive remediation program

          2. Age 18 - 55

          3. Inpatients

          4. DSM-IV diagnosis of schizophrenia (all subtypes) with illness duration &gt;5 years

          5. Auditory and visual acuity adequate to complete cognitive tests

          6. Stable dose of oral atypical antipsychotic for at least 4 weeks

          7. Total PANSS score &gt; 60

          8. RBANS total score â‰¤ 80

          9. MMSE score of greater than or equal to 24

         10. Good physical health determined by physical examination, laboratory tests

         11. Capacity and willingness to give written informed consent

        Exclusion Criteria:

          1. Inability to read or speak English

          2. Documented disease of the central nervous system

          3. History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g.
             mental retardation)

          4. Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal,
             pulmonary or hematologic conditions

          5. HIV +

          6. Patients diagnosed with substance dependence

          7. Currently participating in another experimental study, except for the parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Lindenmayer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Psychiatric Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herbert Lachman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Mc Gurk, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>New Hampshire-Dartmouth Psychiatric Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anzalee Khan, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Manhattan Psychiatric Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Psychiatric Center</name>
      <address>
        <city>Wards Island</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nimh.nih.gov/science-news/2005/brain-scans-reveal-how-gene-may-boost-schizophrenia-risk.shtml</url>
    <description>NIMH Press: Brain Scans Reveal How Gene May Boost Schizophrenia Risk</description>
  </link>
  <link>
    <url>http://en.wikipedia.org/wiki/COMT</url>
    <description>Wikipedia: Catechol-O-methyl transferase</description>
  </link>
  <link>
    <url>http://ghr.nlm.nih.gov/gene=comt</url>
    <description>COMT on National Library of Medicine</description>
  </link>
  <reference>
    <citation>Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res. 2007 Feb;90(1-3):86-96. Epub 2006 Nov 22.</citation>
    <PMID>17123785</PMID>
  </reference>
  <reference>
    <citation>Bosia M, Bechi M, Marino E, Anselmetti S, Poletti S, Cocchi F, Smeraldi E, Cavallaro R. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett. 2007 May 7;417(3):271-4. Epub 2007 Mar 2.</citation>
    <PMID>17383818</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Manhattan Psychiatric Center</investigator_affiliation>
    <investigator_full_name>Jean-Pierre Lindenmayer</investigator_full_name>
    <investigator_title>Clinical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

